Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 11/20 | 0.42 |
| ▸ | AGTR2 | P50052 | 10/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9872036 | 0.93 | AGTR1 (0.41) | AGTR1AGTR2TLR7 | |
| SCHEMBL9872006 | 0.88 | AGTR1 (0.41) | AGTR1AGTR2TLR7KDM4EMEN1 | |
| SCHEMBL9871043 | 0.87 | AGTR2 (0.40) | AGTR1AGTR2 | |
| SCHEMBL9871107 | 0.86 | AGTR1 (0.42) | AGTR1AGTR2TLR7KDM4EMEN1 | |
| SCHEMBL9874853 | 0.85 | AGTR1 (0.40) | AGTR1AGTR2TLR7KDM4EMEN1 | |
| SCHEMBL9872818 | 0.85 | AGTR1 (0.42) | AGTR1AGTR2TLR7KDM4EMEN1 | |
| SCHEMBL9871710 | 0.85 | AGTR1 (0.42) | AGTR1AGTR2TLR7KDM4EMEN1 | |
| SCHEMBL9879548 | 0.85 | AGTR1 (0.42) | AGTR1AGTR2TLR7KDM4EMEN1 | |
| SCHEMBL9874210 | 0.84 | AGTR1 (0.42) | AGTR1AGTR2TLR7KDM4EMEN1 | |
| SCHEMBL9874430 | 0.84 | AGTR1 (0.44) | AGTR1AGTR2TLR7KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1991019715-A1 | 1H-SUBSTITUTED-IMIDAZO[4,5-d]PYRIDAZINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. (US) | 1991-12-26 | — | — | WO | disclosed |